ORFV: A novel oncolytic and immune stimulating parapoxvirus therapeutic

Molecular Therapy

Volumn 20, Issue 6, 2012, Pages 1148-1157

  Rintoul, Julia L ^a   Lemay, Chantal G ^a   Tai, Lee Hwa ^a   Stanford, Marianne M ^a   Falls, Theresa J ^a   De Souza, Christiano T ^a   Bridle, Byram W ^b   Daneshmand, Manijeh ^a   Ohashi, Pamela S ^c,d   Wan, Yonghong ^b   Lichty, Brian D ^b   Mercer, Andrew A ^e   Auer, Rebecca C ^a   Atkins, Harold L ^a   Bell, John C ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VIVO STUDY; LUNG CANCER; LUNG CLEARANCE; LUNG METASTASIS; LYMPHOCYTE DEPLETION; MOUSE; NATURAL KILLER CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; POXVIRUS; POXVIRUS INFECTION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR IMMUNITY; TUMOR VOLUME; TUMOR XENOGRAFT; VIRUS REPLICATION;

ORF VIRUS; OVIS; PARAPOXVIRUS; UNGULATA;

EID: 84861871116     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.301     Document Type: Article

References (49)

1. Breitbach, CJ, Paterson, JM, Lemay, CG, Falls, TJ, McGuire, A, Parato, KA et al. (2007). Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 15: 1686-1693. (Pubitemid 47289013)
2. Breitbach, CJ, De Silva, NS, Falls, TJ, Aladl, U, Evgin, L, Paterson, J et al. (2011). Targeting tumor vasculature with an oncolytic virus. Mol Ther 19: 886-894.
3. Prestwich, RJ, Ilett, EJ, Errington, F, Diaz, RM, Steele, LP, Kottke, T et al. (2009). Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 15: 4374-4381.
4. Apostolidis, L, Schirrmacher, V and Fournier, P (2007). Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. Int J Oncol 31: 1009-1019.
5. Mastrangelo, MJ, Maguire, HC Jr, Eisenlohr, LC, Laughlin, CE, Monken, CE, McCue, PA et al. (1999). Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6: 409-422. (Pubitemid 129667814)
6. Bridle, BW, Hanson, S and Lichty, BD (2010). Combining oncolytic virotherapy and tumour vaccination. Cytokine Growth Factor Rev 21: 143-148.
7. Kaufman, HL and Bines, SD (2010). OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 6: 941-949.
8. Galivo, F, Diaz, RM, Wongthida, P, Thompson, J, Kottke, T, Barber, G et al. (2010). Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther 17: 158-170.
9. Breitbach, CJ, Burke, J, Jonker, D, Stephenson, J, Haas, AR, Chow, LQ et al. (2011). Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477: 99-102.
10. Haig, D, McInnes, C, Deane, D, Lear, A, Myatt, N, Reid, H et al. (1996). Cytokines and their inhibitors in orf virus infection. Vet Immunol Immunopathol 54: 261-267. (Pubitemid 27035593)
11. Savory, LJ, Stacker, SA, Fleming, SB, Niven, BE and Mercer, AA (2000). Viral vascular endothelial growth factor plays a critical role in orf virus infection. J Virol 74: 10699-10706.
12. Schütze, N, Raue, R, Büttner, M and Alber, G (2009). Inactivated parapoxvirus ovis activates canine blood phagocytes and T lymphocytes. Vet Microbiol 137: 260-267.
13. Weber, O, Siegling, A, Friebe, A, Limmer, A, Schlapp, T, Knolle, P et al. (2003). Inactivated parapoxvirus ovis (Orf virus) has antiviral activity against hepatitis B virus and herpes simplex virus. J Gen Virol 84(Pt 7): 1843-1852. (Pubitemid 36805919)
14. Fachinger, V, Schlapp, T, Strube, W, Schmeer, N and Saalmüller, A (2000). Poxvirus-induced immunostimulating effects on porcine leukocytes. J Virol 74: 7943-7951. (Pubitemid 30641638)
15. Czerny, CP, Zeller-Lue, C, Eis-Hübinger, AM, Kaaden, OR and Meyer, H (1997). Characterization of a cowpox-like orthopox virus which had caused a lethal infection in man. Arch Virol Suppl 13: 13-24. (Pubitemid 127502127)
16. Robinson, AJ and Petersen, GV (1983). Orf virus infection of workers in the meat industry. N Z Med J 96: 81-85. (Pubitemid 13087735)
17. Haig, DM and Mercer, AA (1998). Ovine diseases. Orf. Vet Res 29: 311-326.
18. Lederman, ER, Green, GM, DeGroot, HE, Dahl, P, Goldman, E, Greer, PW et al. (2007). Progressive ORF virus infection in a patient with lymphoma: successful treatment using imiquimod. Clin Infect Dis 44: e100-e103.
19. Lear, A, Hutchinson, G, Reid, H, Norval, M, and Haig, D (1996). Phenotypic characterisation of the dendritic cells accumulating in ovince dermis following primary and secondary orf virus infections. Eur J Dermatol 6: 135-140. (Pubitemid 26099120)
20. Jenkinson, DM, McEwen, PE, Onwuka, SK, Moss, VA, Elder, HY, Hutchinson, G et al. (1990). The pathological changes and polymorphonuclear and mast cell responses in the skin of spcific pathogen-free lambs following primary and secondary challenge with orf virus. Vet Dermatol 2: 1-9.
21. Jenkinson, DM, Hutchison, G and Reid, H (1992). The B and T cell responses to orf virus infection. Vet Derm 3: 57-64.
22. Büttner, M, Czerny, CP, Lehner, KH and Wertz, K (1995). Interferon induction in peripheral blood mononuclear leukocytes of man and farm animals by poxvirus vector candidates and some poxvirus constructs. Vet Immunol Immunopathol 46: 237-250.
23. Haig, DM, Hutchinson, G, Thomson, J, Yirrell, D and Reid, HW (1996). Cytolytic activity and associated serine protease expression by skin and afferent lymph CD8+ T cells during orf virus reinfection. J Gen Virol 77 (Pt 5): 953-961. (Pubitemid 26142329)
24. Haig, DM and McInnes, CJ (2002). Immunity and counter-immunity during infection with the parapoxvirus orf virus. Virus Res 88: 3-16. (Pubitemid 35248097)
25. Haig, D, Deane, D, Percival, A, Myatt, N, Thomson, J, Inglis, L et al. (1996). The cytokine response of afferent lymph following orf virus reinfection of sheep. Vet Dermatol 7: 11-20.
26. Mayr, A, Büttner, M, Wolf, G, Meyer, H and Czerny, C (1989). [Experimental detection of the paraspecific effects of purified and inactivated poxviruses]. Zentralblatt Veterinarmedizin Reihe B 36: 81-99.
27. Yirrell, DL, Vestey, JP and Norval, M (1994). Immune responses of patients to orf virus infection. Br J Dermatol 130: 438-443. (Pubitemid 24204661)
28. Friebe, A, Siegling, A, Friederichs, S, Volk, HD and Weber, O (2004). Immunomodulatory effects of inactivated parapoxvirus ovis (ORF virus) on human peripheral immune cells: induction of cytokine secretion in monocytes and Th1-like cells. J Virol 78: 9400-9411. (Pubitemid 39096549)
29. Friebe, A, Friederichs, S, Scholz, K, Janssen, U, Scholz, C, Schlapp, T et al. (2011). Characterization of immunostimulatory components of orf virus (parapoxvirus ovis). J Gen Virol 92(Pt 7): 1571-1584.
30. Sullivan, JT, Mercer, AA, Fleming, SB and Robinson, AJ (1994). Identification and characterization of an orf virus homologue of the vaccinia virus gene encoding the major envelope antigen p37K. Virology 202: 968-973. (Pubitemid 24254912)
31. Czerny, CP, Waldmann, R and Scheubeck, T (1997). Identification of three distinct antigenic sites in parapoxviruses. Arch Virol 142: 807-821. (Pubitemid 27185684)
32. Buddle, BM, Dellers, RW and Schurig, GG (1984). Contagious ecthyma virusvaccination failures. Am J Vet Res 45: 263-266.
33. Stanford, MM, Shaban, M, Barrett, JW, Werden, SJ, Gilbert, PA, Bondy-Denomy, J et al. (2008). Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther 16: 52-59.
34. Evgin, L, Vähä-Koskela, M, Rintoul, J, Falls, T, Le Boeuf, F, Barrett, JW et al. (2010). Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. Mol Ther 18: 896-902.
35. Wang, M, Bronte, V, Chen, PW, Gritz, L, Panicali, D, Rosenberg, SA et al. (1995). Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 154: 4685-4692.
36. Epaulard, O, Toussaint, B, Quenee, L, Derouazi, M, Bosco, N, Villiers, C et al. (2006). Anti-tumor immunotherapy via antigen delivery from a live attenuated genetically engineered Pseudomonas aeruginosa type III secretion system-based vector. Mol Ther 14: 656-661. (Pubitemid 44480761)
37. Boudreau, JE, Stephenson, KB, Wang, F, Ashkar, AA, Mossman, KL, Lenz, LL et al. (2011). IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells. Cancer Res 71: 2497-2506.
38. Melcher, A, Parato, K, Rooney, CM and Bell, JC (2011). Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther 19: 1008-1016.
39. Martín-Fontecha, A, Thomsen, LL, Brett, S, Gerard, C, Lipp, M, Lanzavecchia, A et al. (2004). Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 5: 1260-1265. (Pubitemid 41057741)
40. Cooper, MA, Fehniger, TA and Caligiuri, MA (2001). The biology of human natural killer-cell subsets. Trends Immunol 22: 633-640. (Pubitemid 33043908)
41. Silva, A, Andrews, DM, Brooks, AG, Smyth, MJ and Hayakawa, Y (2008). Application of CD27 as a marker for distinguishing human NK cell subsets. Int Immunol 20: 625-630. (Pubitemid 351426054)
42. Wise, LM, Savory, LJ, Dryden, NH, Whelan, EM, Fleming, SB and Mercer, AA (2007). Major amino acid sequence variants of viral vascular endothelial growth factor are functionally equivalent during Orf virus infection of sheep skin. Virus Res 128: 115-125. (Pubitemid 47242893)
43. Balassu, TC and Robinson, AJ (1987). Orf virus replication in bovine testis cells: kinetics of viral DNA, polypeptide, and infectious virus production and analysis of virion polypeptides. Arch Virol 97: 267-281.
44. Wang, G, Barrett, JW, Stanford, M, Werden, SJ, Johnston, JB, Gao, X et al. (2006). Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci USA 103: 4640-4645.
45. Stojdl, DF, Lichty, BD, tenOever, BR, Paterson, JM, Power, AT, Knowles, S et al. (2003). VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263-275. (Pubitemid 37329791)
46. Willmon, C, Harrington, K, Kottke, T, Prestwich, R, Melcher, A and Vile, R (2009). Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther 17: 1667-1676.
47. Kirstein, JM, Graham, KC, Mackenzie, LT, Johnston, DE, Martin, LJ, Tuck, AB et al. (2009). Effect of anti-fibrinolytic therapy on experimental melanoma metastasis. Clin Exp Metastasis 26: 121-131.
48. Chakrabarti, S, Brechling, K and Moss, B (1985). Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 5: 3403-3409. (Pubitemid 16233047)
49. Ohashi, PS, Oehen, S, Buerki, K, Pircher, H, Ohashi, CT, Odermatt, B et al. (1991). Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65: 305-317. (Pubitemid 121006060)